Author - Likhil Gajbhiye Published Date - 03-Aug-2026
The quest to develop new medicines is a marathon, a complex and costly endeavor fraught with high failure rates and lengthy timelines. For decades, the pharmaceutical industry has relied on traditional methods of drug discovery, often involving labor...
Author - Likhil Gajbhiye Published Date - 15-Jul-2026
About 44% of large organizations have fully embedded AI in multiple business functions. Many other organizations are testing it through pilots or small projects. This gap shows that full adoption is taking time but interest in AI is rising. This conv...
Author - Likhil Gajbhiye Published Date - 14-Jul-2026
GLP-1 companion nutrition means foods and drinks made for people taking GLP-1 weight-loss medicines. Roughly 18% of U.S. adults now use a GLP-1 medication, making this a fast-growing consumer group. These medicines reduce appetite and change eating h...
Author - Likhil Gajbhiye Published Date - 13-Jul-2026
In 2026, AI chip memory shortage is affecting the chip industry. Memory producers are rising the production of High Bandwidth Memory (HBM) for data centers. This results in reduced general DRAM availability. The demand for advanced computing is high,...
GLP-1 drugs are no longer limited to diabetes care. In a some years, they have become the fastest-growing drug category in pharmaceutical history. Drugs like Ozempic, Wegovy, and Mounjaro are driving high demand in global markets. Analysts expect the...